Columbus, Georgia 31904

  • Staphylococcus Aureus Bacteremia


This study will evaluate the maximum safe dose of the true human monoclonal antibody, 514G3, in the treatment of patients with Staphylococcus Aureus bacteremia. Preliminary evidence of efficacy will be evaluated as well. Patients will receive 514G3 plus antibiotics or placebo plus antibiotics in approximately a 3 to 1 ratio.


Inclusion Criteria: 1. One or more blood cultures positive for staphylococcus aureus within 2 days of initiating treatment with 514G3. 2. Temperature ≥ 38.0°C 3. Age ≥18, male or female subjects. 4. Adequate renal function, defined by serum creatinine ≤ 2 times the upper limit of normal (ULN). 5. Adequate hepatic function 6. Adequate bone marrow function 7. For women of childbearing potential (WOCBP), a negative serum pregnancy test result at Screening. 8. Signed and dated institutional review board (IRB)/ Ethics Committee (EC)-approved informed consent before any protocol-specific screening procedures are performed. 9. Expected survival of at least 2 months. Exclusion Criteria: 1. Polymicrobial bacteremia. 2. Known or suspected osteomyelitis or meningitis. 3. Patients that are being mechanically ventilated as a result of a pulmonary infection at the time of screening. Mechanical ventilation for other reasons, such as trauma, is acceptable. 4. Presence of any removable infection source (e.g., intravascular line, abscess, or prosthesis) that will not be removed or debrided within 3 days after randomization. 5. Definite or possible left-sided endocarditis, by Modified Duke Criteria, based on screening echocardiogram. Subjects with suspected right-sided endocarditis are permitted. 6. Need for emergent valve surgery at the time of screening, and/or the presence of decompensated heart failure or cardiogenic shock. 7. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent. 8. Infection with human immunodeficiency virus (HIV) and a CD4 count <200 cells/mm3. 9. Subjects with history of hypersensitivity to compounds of similar chemical or biologic composition to 514G3 or any component of its formulations. 10. Women who are pregnant or breastfeeding.



Primary Contact:

Study Chair
Mark Rupp, M.D.
University of Nebraska

Backup Contact:


Location Contact:

Columbus, Georgia 31904
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.